Alnylam completes enrollment in helios-b phase 3 study of investigational vutrisiran in patients with transthyretin-mediated (attr) amyloidosis with cardiomyopathy

Cambridge, mass.--(business wire)--alnylam pharmaceuticals, inc. (nasdaq: alny), the leading rnai therapeutics company, announced today that it has achieved full patient enrollment in its helios-b phase 3 study of vutrisiran, an investigational rnai therapeutic in development for the treatment of cardiomyopathy in patients with transthyretin-mediated (attr) amyloidosis. enrollment was completed, significantly ahead of schedule, with more than 600 attr amyloidosis patients across 123 activated s
ALNY Ratings Summary
ALNY Quant Ranking